Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB S1216 Principal Investigator: Picus, Joel
Title: A Phase III Randomized Trial Comparing Androgen Deprivaton Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (S1216)
Phase: III Disease Site: Prostate
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to find out what effects there are to adding the new investigational drug TAK-700 to standard hormone therapy which is used to treat prostate cancer as compared to the standard of hormone therapy alone.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)